Company intelligence / Profile preview

eMedicus

Ownership: Private
Development stage: Phase 3

Overview

eMedicus is an independent Institutional Review Board providing ethical review and oversight for pharmaceutical-sponsored clinical trials, investigator-initiated studies, and research at healthcare institutions. The company ensures regulatory compliance and participant safety in clinical research but does not itself conduct or sponsor therapeutic programs.

Industry: Contract Research Organization

Drug pipeline

3 assets

talabostat

Phase 3

Indications: Non-small cell lung cancer, Melanoma, Chronic lymphocytic leukemia, Pancreatic cancer

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on eMedicus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eMedicus.

Explore the full profile